| Not Yet Recruiting | Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Mu NCT07283224 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | e-Motion : Promoting Emotion Regulation in Chronic Cancer NCT07236021 | Université Libre de Bruxelles | N/A |
| Recruiting | Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients NCT06133426 | Assistance Publique - Hôpitaux de Paris | N/A |
| Not Yet Recruiting | Bioequivalence Studies of Dasatinib 100 Mg NCT05944783 | Centro de Atencion e Investigacion Medica | Phase 4 |
| Not Yet Recruiting | Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Us NCT07085728 | Eastern Cooperative Oncology Group | Phase 2 |
| Recruiting | A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma NCT07075185 | Kelonia Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS NCT06559033 | University Hospital, Rouen | — |
| Recruiting | Feasibility of a Multi-omics Platform for Hematological Malignancies NCT07445438 | Azienda Ospedaliero-Universitaria di Parma | N/A |
| Recruiting | The Norwegian Immunotherapy in Multiple Myeloma Study NCT06855121 | St. Olavs Hospital | — |
| Recruiting | Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma NCT06245629 | Uppsala University | — |
| Recruiting | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors NCT06911710 | Tianjin Medical University General Hospital | Phase 1 / Phase 2 |
| Completed | Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPR NCT06418750 | Nantes University Hospital | N/A |
| Active Not Recruiting | Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Tr NCT05889221 | Poitiers University Hospital | N/A |
| Unknown | Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM NCT06205823 | Seoul St. Mary's Hospital | — |
| Recruiting | High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) NCT07205523 | Yigeng Cao,MD,PhD | — |
| Recruiting | Limited-duration Teclistamab NCT05932680 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Recruiting | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma NCT05651932 | K36 Therapeutics, Inc. | Phase 1 |
| Recruiting | Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologou NCT05091372 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Corneal Toxicity in Patients Treated by Belantamab Mafodotin NCT05887206 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Completed | Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant NCT05338047 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Terminated | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refract NCT04843579 | Weill Medical College of Cornell University | Phase 2 |
| Terminated | Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Wh NCT04816526 | Cartesian Therapeutics | Phase 2 |
| Active Not Recruiting | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma NCT04782687 | US Oncology Research | Phase 2 |
| Completed | Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden NCT04760184 | Uppsala University | — |
| Active Not Recruiting | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnose NCT04009109 | Alliance Foundation Trials, LLC. | Phase 2 |
| Unknown | CTFEA Myeloma Study NCT04364724 | Tel-Aviv Sourasky Medical Center | — |
| Recruiting | A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment NCT04268199 | AHS Cancer Control Alberta | Phase 2 |
| Terminated | The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative De NCT04242121 | Ivan S Moiseev | — |
| Completed | Effect of Vitamin C in Autologous Stem Cell Transplantations NCT03964688 | Maastricht University Medical Center | Phase 2 |
| Completed | Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma NCT03891914 | University Hospital, Bordeaux | Phase 3 |
| Terminated | Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myelo NCT03910439 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Rehabilitation Needs of the Malaysian Haematological Cancer Survivors NCT04236063 | University of Malaya | — |
| Completed | T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma NCT03958656 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Fluciclovine PET/CT in Multiple Myeloma Patients NCT03966443 | Oslo University Hospital | — |
| Unknown | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Mali NCT03607643 | Leaf Vertical Inc. | Phase 1 / Phase 2 |
| Unknown | Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive NCT03992170 | Azienda Ospedaliera Universitaria Senese | Phase 2 |
| Active Not Recruiting | T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma NCT03602612 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Pati NCT04065789 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Withdrawn | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma NCT03191981 | University of Leeds | Phase 1 / Phase 2 |
| Unknown | CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma NCT03150316 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Unknown | Collection of Additional Data Followed the Study IFM 2013-04 NCT03089411 | Nantes University Hospital | — |
| Unknown | CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma NCT03051841 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Withdrawn | Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma NCT02447055 | Washington University School of Medicine | EARLY_Phase 1 |
| Completed | Study of the Immune Response After Vaccination in Multiple Myeloma Patients NCT02294487 | Wake Forest University Health Sciences | — |
| Completed | Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma NCT02215967 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Comprehensive Frailty Assessment NCT02033928 | Ohio State University Comprehensive Cancer Center | — |
| Terminated | Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma NCT01239368 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |